79 results about "Genus Bifidobacterium" patented technology

The present invention relates to bifidobacterium breve CCFM1025, its fermented food and application thereof. Bifidobacterium breve CCFM1025 of the present invention can improve the depression-like behavior of depressed mice, increase the levels of 5-hydroxytryptophan, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice, and reduce the levels of 5-hydroxytryptophan in the serum of depressed mice. Corticosterone levels, increased serum 5-hydroxytryptamine levels in depressed mice, improved intestinal flora disturbance in depressed mice, decreased intestinal Veillonellaceae abundance, increased the abundance of Bifidobacteria and Mycoplasmaceae , increase the α-diversity of intestinal flora, reduce the occurrence of inflammatory bowel disease and obesity; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the level of 5-hydroxytryptophan in this cell Secretion, specifically providing precursors for the synthesis of 5-HT in the brain. It has broad application prospects.

This invention relates to the use of a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis strain 420 (B420) for use in reducing food, energy and / or fat intake.

A method of producing a fermented milk characterized by comprising conducting the fermentation with the use of, as lactic acid bacteria, a bacterium belonging to the genus Bifidobacterium and a bacterium belonging to the genus Lactococcus which has the following mycological properties: (1) such a fermentability that, in the case where the bacterium is cultured in a 10% reduced skim milk medium at a temperature of from 25 to 37 degrees centigrade for 16 hours, the medium is solidified; (2) such an effect of promoting the growth of Bifidobacterium longum that, in the case where the bacterium is cultured together with Bifidobacterium longum in the above-described medium and the pH value attains 4.4 to 4.6, the bifidobacterial count amounts to 5x10<8> CFU / g or more; and (3) such an effect of promoting the storage survival of Bifidobacterium longum that, in the case where the bacterium is cultured together with Bifidobacterium longum in the above-described medium, quenched at the point when the pH value attains 4.4 to 4.6 and then stored at 10 degrees centigrade for 2 weeks, the survival rate of Bifidobacterium longum amounts 30% or more; and a fermented milk produced by this production method.

A composition and method for the treatment of chronic sinusitis in which a composition containing desirable colonial bacteria is applied externally in the form of either a spray or a flush. The bacteria are selected from the genus Lactobacillus and the genus Bifidobacterium. The selected bacteria are provided in a therapeutically effective amount in a water solution.

The present invention relates to a composition comprising Bifidobacterium bacteria for use for reducing intestinal gas production in an individual.

A polysaccharide comprises galactose, glucose, rhamnose and pyruvic acid as constituents, the galactose, glucose and rhamnose being contained at a molar ratio of 4:2:1 and the pyruvic acid being contained in an amount of 4 to 7% by mass. The polysaccharide can be produced by culturing cells of Bifidobacterium longum strain JBL05 (NITE BP-82) under anaerobic conditions.

The present invention addresses the problem of providing an agent for degrading an opioid peptide or a composition for degrading an opioid peptide which requires no restriction on diet, shows no sideeffects even if used regularly and, therefore, can be continuously used free from anxiety. To solve this problem, provided are an agent for degrading an opioid peptide, a composition for degrading anopioid peptide, a medicinal composition for degrading an opioid peptide and a food or beverage composition for degrading an opioid peptide, each comprising, as an active ingredient, a bacterium belonging to the genus Bifidobacterium, a culture of the bacterium and / or treated cells of the bacterium.

The invention relates to probiotic bacterial strains and symbiotic composition containing the same intended for infant food. The present invention relates to a selection of probiotic strains belongingto the genus Bifidobacterium and to a symbiotic composition containing the same, intended for feeding infants.

The present invention provides a shuttle vector for a microorganism of the genus Bifidobacterium (BM) and Escherichia coli having a wide host range and a large copy number in BM and capable of highly expressing a desired protein when used as an expression vector; an expression vector capable of expressing a desired gene in BM by use of the shuttle vector; BM transformed with the expression vector; and an antitumor agent comprising the BM as an active ingredient. The vector comprises a pTB6-derived region portion comprising a replication origin (oriV)-repB region of pTB6 but not comprising MembB, MobA, OrfI, and oriT regions of pTB6 and an Escherichia coli-derived plasmid portion comprising a replication origin (oriC) region of Escherichia coli but having deleted DNA encoding an N-terminal region of an ampicillin resistance gene (ampR) expression product -lactamase, and constitute a shuttle vector for Escherichia coli with a BM having an average copy number of 6 to 30.